Dr Catherine Lucas

Dr Catherine Lucas
BPharm, MBBS, FRACP, FAANMS, Nuclear Medicine Physician

Catherine developed her interest in theranostics during her advanced training in nuclear medicine at the Royal Brisbane and Women’s Hospital.

Languages spoken


Expert in

Prostate cancer



Hurstville (Oncology)
Hurstville (Oncology)
-33.96416762029818, 151.1004695691989

Specialises in

Prostate cancer
Condition/Cancer/Prostate Cancer



Special clinical interest in nuclear medicine - theranostics

Catherine is a dual-accredited nuclear medicine physician and clinical pharmacologist. She enjoys working clinically for GenesisCare Theranostics and additionally as a staff specialist clinical academic, holding positions with the University of Newcastle and Hunter New England Local Health District, in nuclear medicine and clinical pharmacology. Her track record includes authoring multiple peer-reviewed publications.

Clinical interests

  •  Dr Lucas is also interested in clinical pharmacology

Professional memberships

  • ANZSNM - Australian and New Zealand Society of Nuclear Medicine
  • ANZUP – Australian and New Zealand Urogenital and Prostate Cancer Trials Group
  • ASCEPT - Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists
  • BPS - British Pharmacological Society
  • IATDMCT - International Association of Therapeutic Drug Monitoring and Clinical Toxicology


  • Patel J, Lucas CJ, Margalit M, Martin JH. Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain. Journal of Pain and Palliative Care Pharmacotherapy. 2018;32(2-3):116-123.
  • Ryan J, Patel J, Lucas CJ, Martin JH. Optimal cancer drug dosing in adolescents: new issues and the old unaddressed ones. Internal Medicine Journal 2018;48:1023-1027.
  • Lucas CJ, Galettis P, Song S, Solowij N, Reuter SE, Schneider J, Martin JH. Cannabinoid disposition after human intraperitoneal use: an insight into intraperitoneal pharmacokinetic properties in metastatic cancer. Clinical Therapeutics 2018;40(9):1442-1447.
  • Lucas C, Martin J. Pharmacokinetic-guided Dosing of New Oral Cancer Agents. The Journal of Clinical Pharmacology 2017;57(S10):S78-S98.
  • Lucas C, Goodman S, Smith J, Burge M, Wyld D, Ravi Kumar A. Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate. Poster presented at: 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; 2016 Mar 9-11; Barcelona, Spain.